ArticleWorld journal of gastroenterology2025
Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of prognostic nutritional index with all-cause and CVD mortality in hypertensive individuals.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation is closely related to survival and disease progression in patients with cancer. However, the predictive value of inflammation-based scores for survival in patients with hepatocellular carcinoma (HCC) treated with Lenvatinib has not been fully elucidated.
aimTo compare different inflammation scores' prognostic values, and establish novel nomogram for predicting overall survival (OS) in HCC patients on Lenvatinib.
methodsIn total, 144 patients with HCC treated with Lenvatinib were enrolled in this study. The prognostic value of pre-treatment inflammation-based scores was retrospectively analyzed, including the platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, lymphocyte-to-C-reactive protein ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, C-reactive protein-to-albumin ratio, and prognostic nutritional index (PNI). Kaplan-Meier survival curves and time-dependent receiver operating characteristic analysis were used to assess predictive accuracy. Univariate and multivariate Cox regression analyses were conducted to identify prognostic factors predicting OS and construct a prognostic nomogram.
resultsAll the inflammation-based scores demonstrated good discrimination in terms of OS (all
conclusionThe PNI is a prognostic indicator for assessing OS in patients with HCC treated with Lenvatinib and is superior to other inflammation-based scores in predicting OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.